US Pharma MarketingThe post EAN 2026: NeuroDerm spotlights Onerji fall reduction in advanced Parkinson’s disease appeared first on Clinical Trials Arena.
EAN 2026: NeuroDerm spotlights Onerji fall reduction in advanced Parkinson’s disease
Additional data on fall reduction could help give NeuroDerm's Onerji a competitive edge. Additional data on fall reduction could help give NeuroDerm's Onerji a competitive edge. Addressing falls in Parkinson’s patients is important because they drive injury, loss of patients’ independence, and caregiver burden. Credit: Antonio Marca/Shutterstock.com. On June 29, at the 12 th Congress of the European Academy of Neurology (EAN) 2026, NeuroDerm presented post hoc analysis from the pivotal Phase III BouNDless (NCT04006210) study. The presentation highlighted findings supporting Onerji (ND0612), a continuous 24-hour subcutaneous infusion of liquid levodopa and carbidopa (LD/CD), for reducing falls in patients with…
Additional data on fall reduction could help give NeuroDerm's Onerji a competitive edge.
Source: Clinical Trials Arena